{"podcast":{"title":"Good Revenue News","slug":"good-revenue-6621493","podcast_index_feed_id":6621493,"rss_url":"https://feeds.acast.com/public/shows/64c1fb4a8e16bd00116ffd75","website_url":"https://goodrevenue.io/","image_url":"https://assets.pippa.io/shows/64c1fb4a8e16bd00116ffd75/1782100647082-1411d5db-bbf4-462d-a5ef-69850dbc8f46.jpeg","author":"Neeta Bidwai","episode_count":203,"summary":"Sharp, data-driven business news analysis exposing context and consequences across AI, geopolitics, energy, science, and global markets so you can make sense of chaos in this particular timeline. Hosted on Acast. See acast.com/privacy for more information.","last_synced_at":"2026-07-16T12:19:51.516912+00:00","page_url":"https://stenobird.com/podcast/good-revenue-6621493"},"episode":{"title":"Ozempic Just Got Cheap Enough to Change the Entire World","slug":"ozempic-just-got-cheap-enough-to-change-the-entire-world","published_at":"2026-03-27T13:00:00+00:00","page_url":"https://stenobird.com/podcast/good-revenue-6621493/ozempic-just-got-cheap-enough-to-change-the-entire-world","show_page_url":"https://stenobird.com/podcast/good-revenue-6621493","url":"https://shows.acast.com/good-revenue/episodes/ozempic-boom-just-got-global-pricing-power-ai-targeting-to-r","audio_url":"https://sphinx.acast.com/p/open/s/64c1fb4a8e16bd00116ffd75/e/69c5c1f8f4bf09c599ae04f8/media.mp3","summary":"A blockbuster drug collapsing from $1,000 to $15 looks like a pricing story. It isn’t. It is a signal that control over human behavior, demand, and consumption is shifting fast. Between generics, new science, and AI-driven optimization, entire industries tied to addiction, food, and habit-driven spending may face structural decline. This episode breaks down why this disruption was inevitable and what happens next. CHAPTERS 00:00 $1,000 drug drops to $15 overnight 00:30 The real story behind the price collapse 00:56 Patent cliff and global generics surge 01:40 Pricing pressure spreads beyond India 02:30 Who controls the pipeline 03:40 New research changes expectations 05:20 AI enters dosing and drug discovery 06:30 This becomes an economic story 07:00 Workforce and GDP implications 08:15 Spending shifts across industries 09:15 What breaks next SOURCES - Affordable GLP-1 Options Emerging in India and Beyond (CNBC): https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html - Global Impact of Ozempic Generics Expanding to China and Canada (NYT): https://www.nytimes.com/2026/03/19/health/ozempic-wegovy-generic-india-china-canada.html - Worldwide Reactions to Cheaper GLP-1 Drugs (BBC Analysis): https://www.bbc.com/news/articles/cx2g4411en3o - AI Optimizing Weight Loss Outcomes: https://www.sciencedirect.com/science/article/abs/pii/S2405457725003821 - Personalized Semaglutide Therapy with Artificial Intelligence: https://ai.jmir.org/2026/1/e86960 - Breakthroughs in GLP-1 Drug Engineering: https://www.sciencedirect.com/science/article/pii/S1359644625000467 - Cutting-Edge Ozempic Alternatives in Research: https://www.nature.com/articles/s41586-025-08683-y - Stanford Research on New Ozempic Rivals: https://med.stanford.edu…","meta_description":"A blockbuster drug collapsing from $1,000 to $15 looks like a pricing story. It isn’t. It is a signal that control over human behavior, demand, and consum…","key_points":[],"chapters":[],"topics":[],"duration_seconds":618,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/good-revenue-6621493/episodes/ozempic-just-got-cheap-enough-to-change-the-entire-world/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/good-revenue-6621493/ozempic-just-got-cheap-enough-to-change-the-entire-world.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}